GGTI 2133 (trifluoroacetate salt)

GGTI 2133 is a peptidomimetic inhibitor of geranylgeranyl transferase type I (GGTase I, IC50 = 38 nM). It is 140-fold selective for GGTase I over farnesyltransferase (IC50 = 5,400 nM). In vitro, it inhibits geranylgeranylation of RAP1A (IC50 = 10 µM) without inhibiting farnesylation of H-Ras (IC50 = >30 µM). It also inhibits cell growth and decreases migration and invasion of oral squamous cell carcinoma (OSSC) cells to 75, 45, and 27% of control values, respectively. GGTI 2133 (5 mg/kg per day, i.p.) prevents ovalbumin-induced eosinophil infiltration into airways in a mouse model of allergic bronchial asthma but does not prevent an increase in chemokines. It also blocks naloxone-induced contraction of ileum isolated from rats with morphine withdrawal syndrome and dose-dependently decreases withdrawal severity in vivo (ED50 = 0.076 mg/kg).Formal Name: N-[4-[(1H-imidazol-5-ylmethyl)amino]-2-(1-naphthalenyl)benzoyl]-L-leucine, 2,2,2-trifluoroacetate salt. CAS Number: 1217480-14-2. Molecular Formula: C27H28N4O3 . XCF3COOH. Formula Weight: 456.5. Purity: >95%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMSO: 25 mg/ml. lambdamax: 222, 285 nm. SMILES: O=C(N[C@H](C(O)=O)CC(C)C)C1=CC=C(NCC2=CNC=N2)C=C1C3=C4C(C=CC=C4)=CC=C3.FC(F)(C(O)=O)F. InChi Code: InChI=1S/C27H28N4O3.C2HF3O2/c1-17(2)12-25(27(33)34)31-26(32)23-11-10-19(29-15-20-14-28-16-30-20)13-24(23)22-9-5-7-18-6-3-4-8-21(18)22,3-2(4,5)1(6)7/h3-11,13-14,16-17,25,29H,12,15H2,1-2H3,(H,28,30)(H,31,32)(H,33,34),(H,6,7)/t25-,/m0./s1. InChi Key: FXXUNOYBYJFSRB-UQIIZPHYSA-N.